Assessment Status |
Awaiting full HTA submission from Applicant |
HTA ID |
24033 |
Drug |
Omaveloxolone |
Brand |
Skyclarys® |
Indication |
For the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older |
Rapid review commissioned |
02/08/2024 |
Rapid review completed |
29/08/2024 |
Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of omaveloxolone compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE |
25/09/2024 |
Pre-submission consultation with Applicant |
04/02/2025 |